Download:
pdf |
pdfOMB No. 3117-0016/USITC No. 14-1-3271; Expiration Date: 6/30/2017
(No response is required if currently valid OMB control number is not displayed)
U.S. PRODUCERS’ QUESTIONNAIRE
ELECTROLYTIC MANGANESE DIOXIDE FROM AUSTRALIA AND CHINA
This questionnaire must be received by the Commission by no later than August 20, 2014
See the Instruction Booklet for filing instructions.
The information called for in this questionnaire is for use by the United States International Trade Commission in
connection with its review of the antidumping duty orders concerning electrolytic manganese dioxide (“EMD”) from
Australia and China (Inv. Nos. 731-TA-1124 and 1125 (Review)). The information requested in the questionnaire is
requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed
can result in a subpoena or other order to compel the submission of records or information in your firm’s possession (19
U.S.C. § 1333(a)).
Name of firm
Address
City
State
Zip Code
World Wide Web address
Has your firm produced EMD (as defined in the instruction booklet) at any time since January 1, 2008?
NO
(Sign the certification below and promptly return only this page of the questionnaire to the Commission)
YES
(Read the instruction booklet carefully, complete all parts of the questionnaire, and return the entire
questionnaire to the Commission so as to be received by the date indicated above)
Return questionnaire via the U.S. International Trade Commission Drop Box by clicking
on the following link: https://dropbox.usitc.gov/oinv/ (use the following PIN: EMDAC)
CERTIFICATION
I certify that the information herein supplied in response to this questionnaire is complete and correct to the best of my knowledge
and belief and understand that the information submitted is subject to audit and verification by the Commission.
By means of this certification I also grant consent for the Commission, and its employees and contract personnel, to use the
information provided in this questionnaire and throughout this proceeding in any other import-injury proceedings or reviews
conducted by the Commission on the same or similar merchandise.
I acknowledge that information submitted in this questionnaire response and throughout this proceeding may be used by the
Commission, its employees, and contract personnel who are acting in the capacity of Commission employees, for developing or
maintaining the records of this proceeding or related proceedings for which this information is submitted, or in internal audits and
proceedings relating to the programs and operations of the Commission pursuant to 5 U.S.C. Appendix 3. I understand that all
contract personnel will sign non-disclosure agreements.
Name of Authorized Official
Title of Authorized Official
Date
Phone:
Signature
Email address
Fax:
Business Proprietary
U.S. Producers’ Questionnaire – EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 2
PART I.—GENERAL INFORMATION
The questions in this questionnaire have been reviewed with market participants to ensure that issues of
concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as
possible. Public reporting burden for this questionnaire is estimated to average 50 hours per response,
including the time for reviewing instructions, searching existing data sources, gathering the data needed,
and completing and reviewing the questionnaire. Send comments regarding the accuracy of this burden
estimate or any other aspect of this collection of information, including suggestions for reducing the
burden, to the Office of Investigations, U.S. International Trade Commission, 500 E Street, SW,
Washington, DC 20436.
I-1a.
OMB statistics.--Please report below the actual number of hours required and the cost to your
firm of preparing the reply to this questionnaire and completing the form.
Hours
Dollars
I-1b.
OMB feedback.--We are interested in any comments you may have for improving this
questionnaire in general or the clarity of specific questions. Please attach such comments to your
firm’s response or send them to the above address.
I-2.
Establishments covered.--Provide the city, state, zip code, and brief description of each
establishment(s) covered by this questionnaire (see page 3 of the instruction booklet for reporting
guidelines). If your firm is publicly traded, please specify the stock exchange and trading symbol
in the footnote to the table.
Establishments
Covered1
City, State
Zip (5 digit)
Description
1
2
3
4
5
6
1
I-3.
Additional discussion on establishments consolidated in this questionnaire:
Position regarding continuation of order.--Does your firm support or oppose continuation of
the antidumping duty order currently in place for EMD from the following countries?
Country
Australia
China
Support
Oppose
Take no position
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 3
PART I.--GENERAL INFORMATION--Continued
I-4.
Ownership.--Is your firm owned, in whole or in part, by any other firm?
No
Yes--List the following information.
Firm name
I-5.
Address
Related SUBJECT importers/exporters.--Does your firm have any related firms, either
domestic or foreign, that are engaged in importing EMD from Australia and/or China into the
United States or that are engaged in exporting EMD from Australia and/or China to the United
States?
No
Yes--List the following information.
Firm name
I-6.
Extent of
ownership
(percent)
Address
Affiliation
Related NONSUBJECT importers/exporters.--Does your firm have any related firms, either
domestic or foreign, that are engaged in importing EMD from countries other than Australia
and/or China into the United States or that are engaged in exporting EMD from countries other
than Australia and/or China to the United States?
No
Yes--List the following information.
Firm name and country
Address
Affiliation
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 4
PART I.--GENERAL INFORMATION--Continued
I-7.
Related producers.--Does your firm have any related firms, either domestic or foreign, that are
engaged in the production of EMD?
No
Yes--List the following information.
Firm name
I-8.
Address
Affiliation
Business plan.--In Parts II and IV of this questionnaire we request a copy of your company’s
business plan. Does your company or any related firm have a business plan or any internal
documents that describe, discuss, or analyze expected market conditions for EMD?
No
Yes
If yes, please provide the requested documents. If you are not providing
the requested documents, please explain why not.
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 5
PART II.--TRADE AND RELATED INFORMATION
Further information on this part of the questionnaire can be obtained from Cynthia Trainor (202-2053354, [email protected]). Supply all data requested on a calendar-year basis.
II-1.
Contact information.-- Please identify the responsible individual and the manner by which
Commission staff may contact that individual regarding the confidential information submitted in
part II.
Name
Title
Email
Telephone
Fax
II-2.
Changes in operations.--Please indicate whether your firm has experienced any of the following
changes in relation to the production of EMD since January 1, 2008.
(check as many as appropriate)
plant openings
plant closings
relocations
expansions
acquisitions
consolidations
prolonged shutdowns or
production curtailments
revised labor agreements
other (e.g., technology)
(please describe)
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 6
PART II.--TRADE AND RELATED INFORMATION--Continued
II-3.
Anticipated changes in operations.--Does your firm anticipate any changes in the character of
your firm’s operations or organization (as noted above) relating to the production of EMD in the
future?
No
Yes--Supply details as to the time, nature, and significance of such changes
and provide underlying assumptions, along with relevant portions of
business plans or other supporting documentation that address this
issue. Include in your response a specific projection of your firm’s
capacity to produce EMD (in short tons) for 2014 and 2015.
For question II-4, if your firm’s response differs for particular orders, please indicate and explain
the particular effect of revocation of specific orders.
II-4.
Anticipated changes in operations in the event the orders are revoked.--Would your firm
anticipate any changes in the character of your firm’s operations or organization (as noted above)
relating to the production of EMD in the future if the antidumping duty order on EMD from
Australia and/or China were to be revoked?
No
Yes--Supply details as to the time, nature, and significance of such changes
and provide underlying assumptions, along with relevant portions of
business plans or other supporting documentation that address this
issue. Include in your response a specific projection of your firm’s
capacity to produce EMD (in short tons) for 2014 and 2015.
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 7
PART II.--TRADE AND RELATED INFORMATION--Continued
II-5a.
Production and capacity.-- Please report your firm’s production of EMD, production of
products made on the same equipment and machinery used to produce EMD, and the combined
production capacity on this shared equipment and machinery in the periods indicated.
(Quantity in short tons)
Item
2008
2009
2010
2011
2012
2013
Overall production capacity
Production of:
EMD
Other products2
1
2
EMD production should equal production data reported in II-7.
Please identify:
II-5b.
Operating parameters.--The production capacity (see definitions in instruction booklet) reported in
II-5a is based on operating
hours per week,
weeks per year.
II-5c.
Capacity calculation.--Please describe the methodology used to calculate overall production capacity
reported in II-5a, and explain any changes in reported capacity.
II-5d.
Production constraints.--Please describe the constraint(s) that set the limit(s) on your firm’s
production capacity.
II-6.
Product shifting.—
(i)
Is your firm able to switch production (capacity) between EMD and other products using the
same equipment and/or labor?
No
(ii)
Yes-- (i.e., have produced other products or are able to produce other
products). Please identify other actual or potential products:
Please describe the factors that affect your firm’s ability to shift production capacity between
products (e.g., time, cost, relative price change, etc.), and the degree to which these factors
enhance or constrain such shifts.
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 8
PART II.--TRADE AND RELATED INFORMATION--Continued
II-7.
Trade data.--Report your firm’s production capacity, production, shipments, inventories, and
employment related to the production of EMD in your firm’s U.S. establishment(s) during the
specified periods. (See definitions in the instruction booklet.)
Quantity (in short tons) and value (in $1,000)
Calendar year
Item
2008
2009
2010
2011
January-June
2012
2013
2013
2014
Average production capacity1
(quantity) (A)
Beginning-of-period inventories
(quantity) (B)
Production (quantity) (C)
U.S. shipments:
Commercial shipments:
quantity (D)
value (E)
Internal consumption:2
quantity (F)
value (G)
Transfers to related firms:2
quantity (H)
value (I)
Export shipments:3
quantity (J)
value (K)
End-of-period inventories
(quantity) (L)
Channels of distribution:
U.S. shipments to distributors
(quantity) (M)
U.S. shipments to end users
(quantity) (N)
Employment data:
Average number of PRWs
(number) (O)
Hours worked by PRWs
(1,000 hours) (P)
Wages paid to PRWs (value)
(Q)
1
The production capacity (see definitions in instruction booklet) reported is based on operating
hours per week,
weeks per year. Please describe the methodology used to calculate production capacity, and explain any changes in
reported capacity (use additional pages as necessary).
2
Internal consumption and transfers to related firms should be valued at fair market value. In the event that your firm
uses a different basis for valuing these transactions, please specify that basis (e.g., cost, cost plus, etc.) and provide value
data using that basis for each of the periods noted above:
3
Identify your firm’s principal export markets:
.
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 9
PART II.--TRADE AND RELATED INFORMATION--Continued
II-7.
Trade data.—Continued
Note.—The table below contains automatic calculations that will appear when you have entered data in the MS
Word form fields in table II-7 on the previous page.
RECONCILIATION OF CHANNEL DATA
Please ensure that the quantities reported for channels of distribution (i.e., lines M and N) in each time period equal the
quantities reported for total U.S. shipments (i.e., lines D, F, and H) in each time period. If the calculated fields below return
values other than zero (i.e., “0”), the data in question II-7 needs to be revised prior to submission to the Commission.
Calendar years
Reconciliation item
2008
Reconciliation should = 0 (if not
revise)
2009
0
2010
0
January-June
2011
0
2012
0
2013
0
2013
0
2014
0
0
RECONCILIATION OF SHIPMENT, INVENTORY AND PRODUCTION DATA
Generally, the data reported for the end-of-period inventories (i.e., line L) should be equal to the beginning-of-period
inventories (i.e., line B), plus production (i.e., line C), less total shipments (i.e., lines D, F, H, and J). Please ensure that any
differences are not due to data entry errors in completing this form, but rather actually reflect your firm’s records; and also
provide any likely explanations for the differences (e.g., theft, loss, damage, record systems issues, etc.).
Calendar years
Reconciliation item
2008
Reconciliation should = 0 (if not,
either revise data or explain the
reason for the discrepancy
below)
2009
0
2010
0
January-June
2011
0
2012
0
2013
0
2013
0
2014
0
0
Explanation for reconciliation not holding:
.
II-8.
Transfers to related firms.--If your firm reported transfers to related firms in question II-7,
please indicate the nature of the relationship between your firm and the related firms (e.g., joint
venture, wholly owned subsidiary), whether the transfers were priced at market value or by a nonmarket formula, whether your firm retained marketing rights to all transfers, and whether the
related firms also processed inputs from sources other than your firm.
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 10
PART II.--TRADE AND RELATED INFORMATION--Continued
II-9.
Purchases.--Other than direct imports, has your firm otherwise purchased EMD since January 1,
2008? (See definitions in the instruction booklet.)
No
Yes-- Please indicate the reasons for your firm’s purchases (if your firms’
reasons differ by source, please elaborate) and report the quantity of
such purchases below for the specified periods
Reasons:
(Quantity in short tons)
Item
2008
2009
2010
2011
2012
2013
PURCHASES FROM U.S.
IMPORTERS1 OF EMD FROM.—
Australia
China
All other countries
PURCHASES FROM DOMESTIC
PRODUCERS:2
1
Please list the name of the importer(s) from which your firm purchased this product. If your firm’s suppliers
differ by source, please identify the source for each listed supplier.
2
Please list the name of the domestic producer(s) from which your firm purchased this product.
II-10.
Toll production.--Since January 1, 2008, has your firm been involved in a toll agreement (see
definition in the instruction booklet) regarding the production of EMD?
No
II-11.
.
FTZ.--Does your firm produce EMD in a foreign trade zone (FTZ)?
No
II-12.
Yes--Name firm(s):
Yes--Identify FTZ(s):
Direct imports.--Since January 1, 2008, has your firm imported EMD?
No
Yes--COMPLETE AND RETURN A U.S. IMPORTERS’
QUESTIONNAIRE
.
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 11
PART II.--TRADE AND RELATED INFORMATION--Continued
For questions II-14 and II-15, if your response differs for particular orders, please indicate and
explain the particular effect of imposition and/or revocation of specific orders.
II-13.
Effect of order.--Describe the significance of the existing antidumping duty orders covering
imports of EMD from Australia and/or China in terms of its effect on your firm’s production
capacity, production, U.S. shipments, inventories, purchases, employment, revenues, costs,
profits, cash flow, capital expenditures, research and development expenditures, and asset values.
You may wish to compare your firm’s operations before and after the imposition of the order.
II-14.
Likely effect of revocation of order.--Would your firm anticipate any changes in its production
capacity, production, U.S. shipments, inventories, purchases, employment, revenues, costs,
profits, cash flow, capital expenditures, research and development expenditures, or asset values
relating to the production of EMD in the future if the antidumping duty orders on EMD from
Australia and/or China were to be revoked?
No
II-15.
Yes--Supply details as to the time, nature, and significance of such changes
and provide underlying assumptions, along with relevant portions of
business plans or other supporting documentation for any trends or
projections you may provide.
Other explanations.--If your firm would like to further explain a response to a question in Part II
that did not provide a narrative response box, please note the question number and the
explanation in the space provided below. Please also use this space to highlight any issues your
firm had in providing the data in this section, including but not limited to technical issues with the
MS Word questionnaire.
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 12
PART III.--FINANCIAL INFORMATION
Address questions on this part of the questionnaire to David Boyland (202-708-4725,
[email protected]).
III-1.
Contact information.-- Please identify the responsible individual and the manner by which
Commission staff may contact that individual regarding the confidential information submitted in
part III.
Name
Title
Email
Telephone
Fax
III-2.
Accounting system.--Briefly describe your firm’s financial accounting system.
A.
When does your firm’s fiscal year end (month and day)?
If your firm’s fiscal year changed during the data-collection period, explain below:
B.1.
Describe the lowest level of operations (e.g., plant, division, company-wide) for which
financial statements are prepared that include EMD:
2.
Does your firm prepare profit/loss statements for EMD:
Yes
No
How often did your firm (or parent company) prepare financial statements (including
annual reports, 10Ks)? Please check relevant items below.
Audited,
unaudited,
annual reports,
10Ks,
10 Qs,
Monthly,
quarterly,
semi-annually,
annually
Accounting basis:
GAAP,
cash,
tax, or
other comprehensive basis
of accounting (specify)
3.
4.
Note: The Commission may request that your company submit copies of its financial statements,
including internal profit-and-loss statements for the division or product group that includes EMD,
as well as those statements and worksheets used to compile data for your firm’s questionnaire
response.
III-3.
Cost accounting system.--Briefly describe your firm’s cost accounting system (e.g., standard
cost, job order cost, etc.).
III-4.
Allocation basis.--Briefly describe your firm’s allocation basis, if any, for COGS, SG&A, and
interest expense and other income and expenses.
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 13
PART III.--FINANCIAL INFORMATION--Continued
III-5.
Impact of bankruptcy reorganization.--To the extent applicable, please describe how
bankruptcy reorganization impacted the company’s EMD operations and financial results during
the period examined. In your response please specify the important bankruptcy-related changes
that impacted costs/expenses as reflected in the pattern of EMD financial results reported to the
Commission (III-19 and III-21). As appropriate, please link the relevant portions of your
response to this question to relevant non-recurring items reported in table III-17A.
III-6.
Grade of EMD produced and sold.--Please indicate whether your company produces and sells
one grade of EMD or multiple grades of EMD and identify as appropriate. In your response,
please also identify the primary characteristics that distinguish the grade and/or grades of EMD
produced. Please specify the relative share of total EMD revenue accounted for by different
grades in 2013 and whether there has been a notable change in these shares during the period
examined.
III-7.
Other products.--Please list the products your firm produces in the facilities in which it produces
EMD, and provide the share of net sales accounted for by these other products in your firm’s
most recent fiscal year.
Products
EMD
Share of sales
%
%
%
%
%
100 %
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 14
PART III.--FINANCIAL INFORMATION--Continued
III-8.
By-product revenue.--Please indicate what by-products, if any, are produced in conjunction with
EMD; e.g., the public description of the production process indicates that certain metals are
extracted during the filtration process. As appropriate, please indicate the disposition of byproduct(s), the extent to which an associated by-product value is recognized in the company’s
formal financial results, and whether or not the EMD cost of goods sold reported in table III-19
and III-21 were reduced in order to reflect the value of associated by-products.
III-9.
Manganese ore supply and pricing.--Please identify the source (company and geographic
location) and primary purchase terms of your manganese ore, as well as how often purchase terms
are renegotiated. Please describe any significant changes in manganese ore supplier, pricing
and/or purchasing terms that occurred during the period.
III-10. Manganese ore mode of shipment.--Please describe the manner and general quantities in which
manganese ore is physically delivered to your company, how often, and extent of further
processing prior to physical delivery. If physical delivery varies over the course of the year,
please indicate in what manner. If there were any notable disruptions in manganese ore supply
during the period examined, please elaborate.
III-11. Manganese ore grade.--Please specify the grades of manganese ore purchased, as reflected in
table III-12, each grade’s share of total purchases in 2013, and whether these relative shares
changed substantially during the period examined. Please also indicate whether the manganese
ore is purchased in a raw or calcined form. If the form of purchased manganese ore changed
during the period examined, please elaborate.
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 15
PART III.--FINANCIAL INFORMATION--Continued
III-12. Manganese ore purchases.--For your firm’s six most recently completed fiscal years, and for the
specified interim periods, please report the volume (in short tons) of manganese ore purchased,
associated purchase cost of manganese ore (in thousand dollars), and associated
transportation/freight costs (in thousand dollars).
Fiscal years ended-Item
2008
2009
2010
2011
January-June
2012
2013
2013
Quantity (in short tons)
Manganese ore short tons purchased
Value (in $1,000)
Purchase cost of manganese ore
Transportation/freight
Total cost (sum of above items)
III-13. Energy inputs.--With respect to electricity and natural gas consumed in the production of EMD,
please describe all long-term supply arrangements, as well as the use of hedging instruments to
mitigate price risk. Please indicate the extent to which these changed during the period
examined.
III-14. Inputs from related parties.--Does your firm purchase inputs (raw materials, labor, energy, or
any other services) used in the production of EMD from any related parties?
Yes--Continue to question III-15.
No--Continue to question III-17.
2014
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 16
PART III.--FINANCIAL INFORMATION--Continued
III-15. Inputs from related parties.--In the space provided below, identify the inputs used in the
production of EMD that your firm purchases from related parties. For “Share of total COGS”
please report this information by relevant input on the basis of your most recently completed
fiscal year. For “Input valuation” please describe the basis, as recorded in the company’s own
accounting system, of the purchase cost from the related party; e.g., the related party’s actual cost,
cost plus, negotiated transfer price to approximate fair market value.
Input
Related party
Input valuation
Share of total COGS
III-16. Inputs from related parties at cost.--All intercompany profit or loss on inputs purchased from
related firms, as well as intra-division profit or loss, should be eliminated from the costs reported
to the Commission in question III-19 and III-21; i.e., costs reported in question III-19 and III-21
should only reflect the related party’s cost and not include an associated profit or loss component.
Reasonable methods for determining and eliminating the associated profit on inputs purchased
from related parties are acceptable.
Has your firm complied with the Commission’s instructions regarding costs associated with
inputs purchased from related parties?
Yes--Please briefly describe how you eliminated intercompany/intra-division profit or (loss)
on inputs purchased/received from related firms/or intra-division units within the same company
to arrive at the actual costs incurred by the related firms/intra-division units.
No—If an inter-company/intra-division profit or (loss) adjustment was applicable, please
explain why this adjustment was not made.
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 17
PART III.--FINANCIAL INFORMATION--Continued
III-17A.Nonrecurring items (charges and gains) included in EMD financial results.--For each annual
and interim period for which financial results are reported in question III-19, please specify all
material (significant) nonrecurring items (charges and gains) in the schedule below, the specific
table III-19 line item where the nonrecurring items are included, a brief description of the relevant
nonrecurring items, and the associated values (in $1,000), as reflected in table III-19; i.e., if an
aggregate nonrecurring item has been allocated to table III-19, only the allocated value amount
included in table III-19 should be reported in the schedule below. Note: The Commission’s
objective here is to gather information only on material (significant) nonrecurring items which
impacted the reported EMD financial results in table III-19.
Fiscal years ended-2008
Nonrecurring item: In this column please
provide a brief description of each
nonrecurring item and indicate the specific
table III-19 line item where the nonrecurring
item is classified.
1.
, classified
2.
, classified
3.
, classified
4.
, classified
5.
, classified
6.
, classified
7.
, classified
2009
2010
2011
January-June
2012
2013
2013
2014
Nonrecurring item: In these columns please report the amount (in $1,000) of the relevant
nonrecurring item reported in table III-19.
III-17B.Classification of identified nonrecurring items (charges and gains) in the accounting books
and records of the company.--If non-recurring items were reported in table III-17A above,
please identify where your company recorded these items in your accounting books and records
in the normal course of business; i.e., III-17A information designates where these items are
reported in table III-19.
III-18. Internal consumption valuation.--To the extent applicable, please describe the basis of the
EMD internal consumption value reported in table III-19; e.g., does it reflect an average value of
EMD purchased at arms-length multiplied by the volume of internally produced and consumed
EMD or some other value? Note: As indicated in the instructions to table III-19, the value
reported for internal consumption should reflect what the company reasonably considers or
estimates to be a fair market value.
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 18
PART III.--FINANCIAL INFORMATION--Continued
III-19. Overall operations on EMD.--Report the revenue and related cost information requested below
on the overall EMD operations of your firm’s U.S. establishment(s).1 Do not report resales of
products. Note that internal consumption and transfers to related parties must be valued at fair
market value and purchases from related firms must be at cost.2 Provide data for your firm’s six
most recently completed fiscal years, and for the specified interim periods. If your firm was
involved in tolling operations (either as the toller or as the tollee), please contact David Boyland
at (202) 708-4725 before completing this section of the questionnaire.
Quantity (in short tons) and value (in $1,000)
Fiscal years ended-Item
2008
2009
2010
2011
2012
2013
Net sales quantities:3
Commercial sales (“CS”)
Internal consumption (“IC”)
Transfers to related firms
(“Transfers”)
Total net sales quantities
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Net sales values:3
Commercial sales
Internal consumption
Transfers to related firms
Total net sales values
4
Cost of goods sold (COGS):
Manganese ore
All other raw materials
Direct labor
Natural gas
Electricity
All other factory costs
Total COGS
Gross profit or (loss)
SG&A expenses:
Selling expenses
General and administrative
expenses
Total SG&A expenses
Operating income (loss)
Other expenses and income:
Interest expense
All other expense items
All other income items
Net income or (loss) before
income taxes
Depreciation/amortization
included above
1
Include only sales (whether domestic or export) and costs related to your U.S. manufacturing operations.
Please eliminate any profits or losses on inputs from related parties pursuant question III-16. For each full-year year period please report the
amount of relevant profit or loss (in $1,000) eliminated from total COGS in this table: 2008
2009
2010
2011
2012
2013
3
Less discounts, returns, allowances, and prepaid freight. The quantities and values should approximate the corresponding shipment quantities
and values reported in Part II of this questionnaire.
4
COGS should include costs associated with CS, IC, and Transfers, as well as export shipments in question II-7.
2
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 19
PART III.--FINANCIAL INFORMATION--Continued
III-19. Overall operations on EMD.—Continued
Quantity (in short tons) and value (in $1,000)
Item
January-June 2013
January-June 2014
3
Net sales quantities:
Commercial sales (“CS”)
Internal consumption (“IC”)
Transfers to related firms (“Transfers”)
Total net sales quantities
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Net sales values:3
Commercial sales
Internal consumption
Transfers to related firms
Total net sales values
Cost of goods sold (COGS):4
Manganese ore
All other raw materials
Direct labor
Natural gas
Electricity
All other factory costs
Total COGS
Gross profit or (loss)
SG&A expenses:
Selling expenses
General and administrative expenses
Total SG&A expenses
Operating income (loss)
Other expenses and income:
Interest expense
All other expense items
All other income items
Net income or (loss) before income taxes
Depreciation/amortization included above
1
Include only sales (whether domestic or export) and costs related to your U.S. manufacturing operations.
Please eliminate any profits or losses on inputs from related firms pursuant question III-16. For each interim period please report
the amount of relevant profit or loss (in $1,000) eliminated from total COGS in this table: interim 2013
interim 2014
3
Less discounts, returns, allowances, and prepaid freight. The quantities and values should approximate the corresponding
shipment quantities and values reported in Part II of this questionnaire.
4
COGS should include costs associated with CS, IC, and Transfers, as well as export shipments in question II-7.
2
Note -- The table above contains calculations that will appear when you have entered data in the MS
word form fields.
III-20. Internal consumption.--With respect to the total EMD sales reported in table III-19, does the
majority represent internal consumption and/or transfers?
Yes-continue to question III-21 below
No-Continue to question III-22 below
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 20
PART III.--FINANCIAL INFORMATION--Continued
III-21. Operations on EMD--commercial (trade) sales only.--For commercial (trade) sales only, report
the revenue and related cost information requested below on the EMD operations of your U.S.
establishment(s).1 2 Provide data for your six most recently completed fiscal years in
chronological order from left to right, and for the specified interim periods. If your firm was
involved in tolling operations (either as the toller or as the tollee) please contact David Boyland,
Auditor at (202) 708-4725 or [email protected] before completing this section of the
questionnaire.
Quantity (in short tons) and value (in $1,000)
Fiscal years ended-Item
2008
2009
2010
2011
2012
2013
Net sales quantities:3
Commercial sales (“CS”)
Net sales values:3
Commercial sales
Cost of goods sold (COGS):4
Manganese ore
All other raw materials
Direct labor
Natural gas
Electricity
All other factory costs
Total COGS
Gross profit or (loss)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
SG&A expenses:
Selling expenses
General and administrative
expenses
Total SG&A expenses
Operating income (loss)
Other expenses and income:
Interest expense
All other expense items
All other income items
Net income or (loss) before
income taxes
Depreciation/amortization
included above
1
Include only sales (whether domestic or export) and costs related to your U.S. manufacturing operations.
Please eliminate any profits or (losses) on inputs from related parties pursuant question III-16. For each full-year year period please report the
amount of relevant profit or loss (in $1,000) eliminated from total COGS in this table: 2008
2009
2010
2011
2012
2013
3
Less discounts, returns, allowances, and prepaid freight. The quantities and values should approximate the corresponding shipment quantities
and values reported in Part II of this questionnaire.
4
COGS should include costs associated with corresponding shipments (U.S. and exports) reported in question II-7.
2
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 21
PART III.--FINANCIAL INFORMATION--Continued
III-21. Operations on EMD--commercial (trade) sales only.--Continued
Quantity (in short tons) and value (in $1,000)
Item
January-June 2013
January-June 2014
3
Net sales quantities:
Commercial sales (“CS”)
Net sales values:3
Commercial sales
Cost of goods sold (COGS):4
Manganese ore
All other raw materials
Direct labor
Natural gas
Electricity
All other factory costs
Total COGS
Gross profit or (loss)
0
0
0
0
0
0
0
0
0
0
SG&A expenses:
Selling expenses
General and administrative expenses
Total SG&A expenses
Operating income (loss)
Other expenses and income:
Interest expense
All other expense items
All other income items
Net income or (loss) before income taxes
Depreciation/amortization included above
1
Include only sales (whether domestic or export) and costs related to your U.S. manufacturing operations.
Please eliminate any profits or (losses) on inputs from related firms pursuant question III-16. For each interim period please report
the amount of relevant profit or loss (in $1,000) eliminated from total COGS in this table: interim 2013
interim 2014
3
Less discounts, returns, allowances, and prepaid freight. The quantities and values should approximate the corresponding
shipment quantities and values reported in Part II of this questionnaire.
4
COGS should include costs associated with corresponding shipments (U.S. and exports) reported in question II-7.
2
Note -- The table above contains calculations that will appear when you have entered data in the MS
Word form fields.
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 22
PART III.--FINANCIAL INFORMATION--Continued
III-22. Financial data reconciliation.--The calculable line items from question III-19 and III-21 (i.e.,
total net sales quantities and values, total COGS, gross profit (or loss), total SG&A, and net
income (or loss)) have been calculated from the data submitted in the other line items. Do the
calculated fields return the correct data according to your firm's financial records ignoring nonmaterial differences that may arise due to rounding?
Yes
No--If the calculated fields do not show the correct data, please double check the
feeder data for data entry errors and revise.
Also, check signs accorded to the post operating income line items; the two
expense line items should report positive numbers (i.e., expenses are positive
and incomes or reversals are negative--instances of the latter should be rare
in those lines) while the income line item also in most instances should have
its value be a positive number (i.e., income is positive, expenses or reversals
are negative).
If after reviewing and potentially revising the feeder data your firm has
provided, the differences between your records and the calculated fields
persist please identify and discuss the differences in the space below.
III-23. Asset values.--Report the total assets (i.e., both current and long-term assets) associated with the
production, warehousing, and sale of EMD. If your firm does not maintain some or all of the
specific asset information necessary to calculate total assets for EMD in the normal course of
business, please estimate this information based upon a method (such as production, sales, or
costs) that is consistent with your firm’s cost allocations in the previous question. Provide data as
of the end of your firm’s six most recently completed fiscal years.
Note: Total assets should reflect net assets after any accumulated depreciation and allowances deducted.
Total assets should be allocated to the subject products if these assets are also related to other products.
Please provide a brief explanation if there are any substantial changes in total asset value during the
period; e.g., due to asset write-offs, revaluation, and major purchases.
Value (in $1,000)
Fiscal years ended-Item
Total assets (net)
2008
2009
2010
2011
2012
2013
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 23
PART III.--FINANCIAL INFORMATION--Continued
III-24. Capital expenditures and research and development expenses.--Report your firm’s capital
expenditures and research and development expenses on EMD. Provide data for your firm’s six
most recently completed fiscal years, and for the specified interim periods.
Value (in $1,000)
Fiscal years ended-Item
2008
2009
2010
2011
January-June
2012
2013
2013
2014
Capital expenditures
Research and development
expenses
III-25. Data consistency and reconciliation.--Please indicate whether your firm’s financial data for
questions III-19, III-21, III-23, and III-24 are based on a calendar year or your firm’s fiscal year:
Calendar year
Fiscal year
Specify fiscal year
Please note the quantities and values reported in question III-19 should reconcile with the data
reported in question II-7 (including export shipments) as long as they are reported on the same
calendar year basis.
Do these data in question III-19 reconcile with data in question II-7?
Yes
No
If no, please explain.
III-26. Other explanations.--If your firm would like to further explain a response to a question in Part
III that did not provide a narrative response box, please note the question number and the
explanation in the space provided below. Please also use this space to highlight any issues your
firm had in providing the data in this section, including but not limited to technical issues with the
MS Word questionnaire.
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 24
PART IV.--PRICING AND MARKET FACTORS
Further information on this part of the questionnaire can be obtained from James Fetzer (202-708-5403,
[email protected]).
Contact information.-- Please identify the responsible individual and the manner by which Commission
staff may contact that individual regarding the confidential information submitted in part IV.
Name
Title
Email
Telephone
Fax
PRICE DATA
IV-1.
This question requests quarterly quantity, f.o.b. value, and U.S.-inland freight and shipping costs
data for your firm’s commercial shipments to unrelated U.S. customers since 2008 of the
following products produced by your firm.
Product 1.--Standard alkaline grade electrolytic manganese dioxide in powder form.
Please note that values should be f.o.b., U.S. point of shipment and should not include U.S.-inland
transportation costs. Values should reflect the final net amount paid to your firm (i.e., should be net
of all deductions for discounts or rebates). See instruction booklet.
During 2008-June 2014, did your firm produce and sell to unrelated U.S. customers any of the
above listed products (or any products that were competitive with these products)?
Yes.--Please complete the following pricing data table(s) as appropriate.
No.--Skip to question IV-2.
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 25
PART IV.--PRICING AND MARKET FACTORS--Continued
IV-1.
Pricing data--Continued.--Report below the quarterly price data1 for pricing products2 produced
and sold by your firm.
Report data in actual pounds and actual dollars (not 1,000s).
(Quantity in pounds; value and U.S.-inland freight and shipping costs in dollars)
Product 1
Quantity
F.o.b. value
U.S.-inland freight and
shipping costs3
Period of shipment
2008:
January-March
April-June
July-September
October-December
2009:
January-March
April-June
July-September
October-December
2010:
January-March
April-June
July-September
October-December
2011:
January-March
April-June
July-September
October-December
2012:
January-March
April-June
July-September
October-December
2013:
January-March
April-June
July-September
October-December
2014:
January-March
April-June
1
Net values (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of
returned goods), f.o.b. your firm’s U.S. point of shipment.
2
Pricing product definitions are provided on the first page of Part IV.
3
Transportation costs to ship U.S.-produced EMD from your firm’s U.S. point of shipment.
Note.--If your firm’s product does not exactly meet the product specifications but is competitive with the specified
product, provide a description of the product. Also, please explain any anomalies in your firm’s reported pricing data.
Product 1:
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 26
PART IV.--PRICING AND MARKET FACTORS--Continued
IV-2.
Price setting.-- How does your firm determine the prices that it charges for sales of EMD (check
all that apply)? If your firm issues price lists, please submit sample pages of a recent list.
Transaction
by
transaction
IV-3.
If other, describe
Annual
total
volume
discounts
No
discount
policy
Other
Describe
Pricing terms.-(a)
What are your firm’s typical sales terms for its U.S.-produced EMD?
Net 30
days
(b)
Net 60
days
2/10 net 30
days
Other
Other (specify)
On what basis are your firm’s prices of domestic EMD usually quoted (check one)?
Delivered
IV-5.
Other
Discount policy.-- Please indicate and describe your firm’s discount policies (check all that
apply).
Quantity
discounts
IV-4.
Contracts
Set
price
lists
F.o.b.
If f.o.b., specify point
Contract versus spot.-- Approximately what share of your firm’s sales of its U.S.-produced
EMD in 2013 was on a (1) long-term contract basis, (2) short-term contract basis, and (3) spot
sales basis?
Long-term
contracts
(multiple deliveries
for more than 12
months)
Share of your
2013 sales
%
Type of sale
Short-term
contracts
(multiple deliveries up
to and including 12
months)
%
Spot sales
(for a single
delivery)
%
Total
(should sum to
100.0%)
0
%
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 27
PART IV.--PRICING AND MARKET FACTORS--Continued
IV-6.
Contract provisions.— Please fill out the table regarding your firm’s typical sales contracts for
EMD (or check “not applicable” if your firm does not sell on a long-term and/or short-term
contract basis).
Typical sales contract
provisions
Item
Average contract duration
Number of days
Price renegotiation (during the
contract period)
Yes
Short-term contracts
Long-term contracts
(multiple deliveries up to
and including 12 months)
(multiple deliveries for more
than 12 months)
No
Quantity
Fixed quantity and/or price
Price
Both
Meet or release provision
Yes
No
Not applicable
IV-7.
Negotiation process.--Please explain the negotiation process, and the frequency of such
negotiations, for your firm’s sales of U.S.-produced EMD to its U.S. battery-producer customers
since January 2008. In addition, please explain the dynamics of the price quote/bid process
between the initial price quote/bid and the final price quote/bid.
Explain the negotiation process
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 28
PART IV.--PRICING AND MARKET FACTORS--Continued
IV-8.
Qualification.— Please fill out the table regarding your firm’s typical sales contracts for U.S.produced EMD (or check “not applicable” if your firm does not sell on a long-term and/or shortterm contract basis).
Typical sales contract provisions
Was your firm required to be qualified as a supplier of U.S.produced EMD?
Yes
No
N/A
If your firm produced more than a single formulation/grade of
EMD, did any such qualification requirement also apply to
each of your firm’s formulation(s)/grade(s) of its U.S.produced EMD?
Does your firm need to separately qualify as a supplier of its
U.S.-produced EMD to each of multiple U.S. plant locations of
each of its U.S. battery-producer customers with more than
one battery producing plant in the United States?
If your firm produced EMD that was more than a single
formulation/grade of EMD, did any such qualification
requirement also apply to each of your firm’s
formulation(s)/grade(s) of its U.S.-produced EMD?
Please identify the purchasers and formulations for which you must qualify
your sales of EMD and explain difference in the qualifications between
products and customers.
IV-9.
Lead times.--What is the typical lead time between a customer’s order and the date of delivery
for your firm’s sales of your firm’s U.S.-produced EMD?
Source
Share of 2013
sales
From inventory
%
Produced to order
%
Total (should sum to 100.0%)
0
%
Lead time (days)
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 29
PART IV.--PRICING AND MARKET FACTORS--Continued
IV-10. Shipping information.-(a)
What is the approximate percentage of the total delivered cost of EMD that is accounted
for by U.S. inland transportation costs?
%
(b)
Who generally arranges the transportation to your firm’s customers’ locations?
your firm
purchaser (check one)
(c)
Indicate the approximate percentage of your firm’s sales of EMD that are delivered the
following distances from your firm’s production facility.
Distance from production facility
Share
Within 100 miles
%
101 to 1,000 miles
%
Over 1,000 miles
%
Total (should sum to 100.0%)
0
%
IV-11. Geographical shipments.-- In which U.S. geographic market area(s) has your firm sold its U.S.produced EMD since January 1, 2008 (check all that apply)?
Geographic area
√ if applicable
Northeast.–CT, ME, MA, NH, NJ, NY, PA, RI, and VT.
Midwest.–IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, and WI.
Southeast.–AL, DE, DC, FL, GA, KY, MD, MS, NC, SC, TN, VA, and WV.
Central Southwest.–AR, LA, OK, and TX.
Mountains.–AZ, CO, ID, MT, NV, NM, UT, and WY.
Pacific Coast.–CA, OR, and WA.
Other.–All other markets in the United States not previously listed, including AK, HI,
PR, and VI, among others.
IV-12. End uses.--List the end uses of the EMD that your firm manufactures. For each end-use product,
what percentage of the total cost is accounted for by EMD and other inputs?
Share of total cost of end use product
accounted for by
End use product
EMD
Total (should sum
to 100.0% across)
Other inputs
%
%
%
%
%
%
0 %
0 %
0 %
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 30
PART IV.--PRICING AND MARKET FACTORS--Continued
IV-13. Changes in end uses.--Have there been any changes in the end uses of EMD since January 1,
2008? Do you anticipate any future changes?
Changes in end uses
No
Yes
Explain
Changes since 2008
Anticipated changes
IV-14. Substitutes.-- Can other products be substituted for EMD?
No
Yes--Please fill out the table.
Substitute
End use in which this
substitute is used
Have changes in the prices of this substitute
affected the price for EMD?
No Yes
Explanation
1.
2.
3.
IV-15. Changes in substitutes.-- Have there been any changes in the number or types of products that
can be substituted for EMD since January 1, 2008? Do you anticipate any future changes?
Changes in
substitutes
Changes since 2008
Anticipated changes
No
Yes
Explain
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 31
PART IV.--PRICING AND MARKET FACTORS--Continued
IV-16. Raw materials.-- Indicate how EMD raw materials prices have changed since January 1, 2008,
and how you expect they will change in the future.
Raw
materials
prices
Fluctuate
with no
Overall
No
Overall
clear
increase change decrease
trend
Explain, noting how raw material
price changes have affected your
firm’s selling prices for EMD.
Changes
since 2008
Anticipated
changes
IV-17. Availability of supply.--Has the availability of EMD in the U.S. market changed since January 1,
2008? Do you anticipate any future changes?
Availability in the U.S.
market
Please explain, noting the countries and reasons for
No Yes the changes.
Changes since 2008:
U.S.-produced product
Subject imports
Nonsubject imports
Anticipated changes:
U.S.-produced product
Subject imports
Nonsubject imports
IV-18. Export constraints.--Describe how easily your firm can shift its sales of EMD between the U.S.
market and alternative country markets. In your discussion, please describe any contracts, other
sales arrangements, or other constraints that would prevent or retard your firm from shifting EMD
between the U.S. and alternative country markets within a 12-month period.
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 32
PART IV.--PRICING AND MARKET FACTORS--Continued
IV-19. Product changes.-- Have there been any significant changes in the product range, product mix,
or marketing of EMD since January 1, 2008? Do you anticipate any future changes?
Changes in
product range,
product mix, or
marketing
No
Yes
Explain
Changes since 2008
Anticipated changes
IV-20. Demand trends.-- Indicate how demand within the United States and outside of the United States
(if known) for EMD has changed since January 1, 2008, and how you anticipate demand will
change in the future. Explain any trends and describe the principal factors that have affected, and
that you anticipate will affect, these changes in demand.
Market
Overall
No
increase change
Fluctuate
Overall
with no
decrease clear trend
Demand since 2008
Within
the United
States
Outside
the United
States
Anticipated future demand
Within
the United
States
Outside
the United
States
Explanation and factors
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 33
PART IV.--PRICING AND MARKET FACTORS--Continued
IV-21. Conditions of competition.-(a) Is the EMD market subject to business cycles (other than general economy-wide conditions)
and/or other conditions of competition distinctive to EMD?
Check all that apply.
Please describe.
No
Skip to question IV-22.
Yes-Business cycles (e.g.
seasonal business)
Yes-Other distinctive
conditions of competition
(b) If yes, have there been any changes in the business cycles or conditions of competition for
EMD since January 1, 2008?
No
Yes
If yes, describe.
IV-22. Price comparisons.--Please compare market prices of EMD in U.S. and non-U.S. markets, if
known. Provide specific information as to time periods and regions for any price comparisons.
IV-23. Market studies.--Please provide as a separate attachment to this request any studies, surveys, etc.
that you are aware of that quantify and/or otherwise discuss EMD supply (including production
capacity and capacity utilization) and demand in (1) the United States, (2) each of the other major
producing/consuming countries, including Australia and/or China, and (3) the world as a whole.
Of particular interest is such data from 2008 to the present and forecasts for the future.
IV-24. Barriers to trade.--Are your firm’s exports of EMD subject to any tariff or non-tariff barriers to
trade in other countries?
No
Yes
If yes, please list the countries and describe any such barriers and
any significant changes in such barriers that have occurred since
2008, or that are expected to occur in the future.
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 34
PART IV.--PRICING AND MARKET FACTORS--Continued
IV-25. Interchangeability.--Is EMD produced in the United States and in other countries
interchangeable (i.e., can they physically be used in the same applications)?
Please indicate A, F, S, N, or 0 in the table below:
A = the products from a specified country-pair are always interchangeable
F = the products are frequently interchangeable
S = the products are sometimes interchangeable
N = the products are never interchangeable
0 = no familiarity with products from a specified country-pair
Country-pair
Australia
China
Japan
South Africa
Other
countries
United States
Australia
China
Japan
South Africa
For any country-pair producing EMD which is sometimes or never interchangeable, please
identify the country-pair and explain the factors that limit or preclude interchangeable use:
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 35
PART IV.--PRICING AND MARKET FACTORS--Continued
IV-26. Factors other than price.--Are differences other than price (e.g., quality, availability,
transportation network, product range, technical support, etc.) between EMD produced in the
United States and in other countries a significant factor in your firm’s purchases of the products?
Please indicate A, F, S, N, or 0 in the table below:
A = such differences are always significant
F = such differences are frequently significant
S = such differences are sometimes significant
N = such differences are never significant
0 = no familiarity with products from a specified country-pair
Country-pair
Australia
China
Japan
South Africa
Other
countries
United States
Australia
China
Japan
South Africa
For any country-pair for which factors other than price always or frequently are a significant
factor in your firm’s purchases of EMD, identify the country-pair and report the advantages or
disadvantages imparted by such factors:
Business Proprietary
U.S. Producers’ Questionnaire - EMD from Australia and China (731-TA-1124 and 1125 (Review))Page 36
PART IV.--PRICING AND MARKET FACTORS--Continued
IV-27. Failed attempts to qualify or sell EMD.-- Did your firm fail in its attempt to sell or qualify its
U.S.-produced EMD to U.S. battery producers since January 2008? Please report the customer
involved, the date(s) of such failed efforts, the formulation(s) of EMD offered and the type(s) of
batteries for which each formulation of your EMD was intended to be used.
No
Yes
Details of failed efforts
Failed to sell
Failed to qualify
IV-28. Failed attempts to supply EMD.-- Did your firm fail to supply, fully or partially, the agreedupon quantity of its U.S.-produced EMD to its U.S. battery-producer customer(s) since January
2008? Please report the U.S. customer involved, the date of the occurrence, the quantity (in short
tons) of EMD, the specific EMD formulation(s) involved, the category(ies) of EMD batteries
affected, and the circumstances of the occurrence.
No
Yes
Details of failed supply
Failed to supply fully
Failed to supply
partially
IV-29. Other explanations.--If your firm would like to further explain a response to a question in Part
IV that did not provide a narrative response box, please note the question number and the
explanation in the space provided below. Please also use this space to highlight any issues your
firm had in providing the data in this section, including but not limited to technical issues with the
MS Word questionnaire.
| File Type | application/pdf |
| File Title | Microsoft Word - Sunset US Producer Questionnaire EMD Review |
| Author | cynthia.trainor |
| File Modified | 2014-07-21 |
| File Created | 2014-07-21 |